GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve (OTCMKTS:GLAXF)
William Barton Thesis GSK plc (NYSE:GSK) trades at low price multiples relative to competitors. At the surface, it looks like a good buy. However, in my opinion, the lower multiples reflect weaker later stage pipeline relative to competitors. Current pipeline will not face significant patent expirations over the next couple of years, but GSK needs…